A phase II study of sequential decitabine and rapamycin in acute myelogenous leukemia.

[1]  H. Döhner,et al.  Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial. , 2021, The Lancet. Oncology.

[2]  Yi Zheng,et al.  Adaptive responses to mTOR gene targeting in hematopoietic stem cells reveal a proliferative mechanism evasive to mTOR inhibition , 2020, Proceedings of the National Academy of Sciences.

[3]  H. Döhner,et al.  Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  M. Tormo,et al.  Evolving treatment patterns and outcomes in older patients (≥60 years) with AML: changing everything to change nothing? , 2020, Leukemia.

[5]  T. Žvirblis,et al.  Outcomes of relapsed or refractory acute myeloid leukemia patients failing venetoclax‐based salvage therapies , 2020, European journal of haematology.

[6]  Xu Huang,et al.  Targeting PI3K/Akt/mTOR in AML: Rationale and Clinical Evidence , 2020, Journal of clinical medicine.

[7]  A. Letai,et al.  Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia. , 2020, The New England journal of medicine.

[8]  Xiaomei Ma,et al.  Clinical outcomes of older patients with AML receiving hypomethylating agents: a large population-based study in the United States. , 2020, Blood advances.

[9]  A. Gural,et al.  Venetoclax is safe and efficacious in relapsed/refractory AML , 2020, Leukemia & lymphoma.

[10]  H. Reikvam,et al.  The PI3K-Akt-mTOR Signaling Pathway in Human Acute Myeloid Leukemia (AML) Cells , 2020, International journal of molecular sciences.

[11]  G. Madlambayan,et al.  The HDAC and PI3K dual inhibitor CUDC-907 synergistically enhances the antileukemic activity of venetoclax in preclinical models of acute myeloid leukemia , 2020, Haematologica.

[12]  Qi Zhang,et al.  Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML. , 2020, Blood.

[13]  F. Ferrara,et al.  Current Therapeutic Results and Treatment Options for Older Patients with Relapsed Acute Myeloid Leukemia , 2019, Cancers.

[14]  M. Konopleva,et al.  Treatment with a 5-day versus a 10-day schedule of decitabine in older patients with newly diagnosed acute myeloid leukaemia: a randomised phase 2 trial. , 2019, The Lancet. Haematology.

[15]  A. Cashen.  10-day decitabine schedule in acute myeloid leukaemia: no extra bang for the buck. , 2019, The Lancet. Haematology.

[16]  J. Scandura,et al.  Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia , 2018, Haematologica.

[17]  M. Konopleva,et al.  Clinical experience with the BCL2‐inhibitor venetoclax in combination therapy for relapsed and refractory acute myeloid leukemia and related myeloid malignancies , 2018, American journal of hematology.

[18]  Shuang Liu,et al.  Targeting PI3K, mTOR, ERK, and Bcl‐2 signaling network shows superior antileukemic activity against AML ex vivo , 2018, Biochemical pharmacology.

[19]  J. Liesveld,et al.  Dueling for dual inhibition: Means to enhance effectiveness of PI3K/Akt/mTOR inhibitors in AML. , 2017, Blood reviews.

[20]  R. Larson,et al.  Efficacy of single-agent decitabine in relapsed and refractory acute myeloid leukemia , 2017, Leukemia & lymphoma.

[21]  Bob Löwenberg,et al.  Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. , 2017, Blood.

[22]  S. Grant,et al.  Co-administration of the mTORC1/TORC2 inhibitor INK128 and the Bcl-2/Bcl-xL antagonist ABT-737 kills human myeloid leukemia cells through Mcl-1 down-regulation and AKT inactivation , 2015, Haematologica.

[23]  S. Capitani,et al.  Targeting PI3K/AKT/mTOR network for treatment of leukemia , 2015, Cellular and Molecular Life Sciences.

[24]  S. Grant,et al.  Rational combination of dual PI3K/mTOR blockade and Bcl-2/-xL inhibition in AML. , 2014, Physiological genomics.

[25]  J. Liesveld,et al.  A phase I study of decitabine and rapamycin in relapsed/refractory AML. , 2013, Leukemia research.

[26]  A. Redig,et al.  Dual mTORC2/mTORC1 Targeting Results in Potent Suppressive Effects on Acute Myeloid Leukemia (AML) Progenitors , 2011, Clinical Cancer Research.

[27]  W. Shannon,et al.  In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. , 2010, Blood.

[28]  J. Dipersio,et al.  Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  J. McCubrey,et al.  Targeting the PI3K/AKT/mTOR signaling network in acute myelogenous leukemia , 2009, Expert opinion on investigational drugs.

[30]  Q. Rao,et al.  Aberrant expression of TSC2 gene in the newly diagnosed acute leukemia. , 2009, Leukemia research.

[31]  H. Koeffler,et al.  Blockade of mTOR signaling potentiates the ability of histone deacetylase inhibitor to induce growth arrest and differentiation of acute myelogenous leukemia cells , 2008, Leukemia.

[32]  S. Chakraborty,et al.  Involvement of TSC genes and differential expression of other members of the mTOR signaling pathway in oral squamous cell carcinoma , 2008, BMC Cancer.

[33]  M. Grever,et al.  Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[34]  S. Morrison,et al.  Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells , 2006, Nature.

[35]  G. Laurent,et al.  Antileukemic activity of rapamycin in acute myeloid leukemia. , 2005, Blood.

[36]  C. Bloomfield,et al.  Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.